DIA
Drug Information Association Logo

Joint DIA/AEMPS Statistics Workshop

Nov 10 2014 9:00AM - Nov 11 2014 4:00PM | Tryp Barcelona Apolo Avinguda del Parallel, 57-59 08004 Barcelona Spain

« Back to Listing

Overview 

The last three annual conferences have been co-sponsored by the EMA, MHRA and BfArM. This year’s event - statistical methodology in clinical research and development - is a joint workshop with the AEMPS, the Spanish Medicines Agency (Agencia Española de Medicamentos y Productos Sanitarios).

Featured Topics 

  • Latest news on emerging regulatory guidance documents for clinical trial methodology
  • Clinical Trial Transparency – practical challenges ahead for statisticians
  • Harmonising sponsor and regulator decision-making across the life-cycle, from dose-finding through benefit-risk and beyond; understanding hurdles and optimising methods with a focus on Bayesian Statistics and quantitative Benefit Risk
  • Therapeutic area special; a focus on biological medicines
  • Clinical Practice Research Datalink tutorial
  • Incorporating real world data into drug development, licensing, re-imbursement and prescribing
  • Risk-based monitoring
  • Increasing the breadth of sponsor / regulator interactions on methodology

Who Should Attend 

Professionals with an interest in the application of, and research into, statistics in the drug development process from the pharmaceutical industry, academia, regulatory and governmental agencies, as well as contract research organisations.

Learning Objectives 

Defining the objective of a clinical trial in the presence of non-adherence to the assigned treatment is crucial for the choice of a proper statistical analysis and the interpretation of the results: the meeting will provide an insight on the different views on the choice of an appropriate estimand (i.e. on what is to be estimated) and the design options and analysis methods related to the selected estimand.

The methodological issues related to the assessment of biosimilarity of biological products for regulatory approval have recently received much attention due to the essential differences between biosimilars and small molecule generics. The meeting will focus on the statistical aspects of the different components in the development of a biosimilar that are required for marketing authorization.

The meeting further aims to illustrate how innovative methods can be used to identify subgroups that benefit in particular from a new treatment and how this knowledge can be integrated into clinical development plans through adaptive and enrichment designs to develop personalised / stratified treatment strategies. Discussions will consider not only the methods themselves, but also how to best implement them in a regulatory context.

Beyond this, the meeting will also serve as a forum for sharing an update on the latest EMA guidance documents and activities, including recent positive opinions.

Hotel & Travel 

DIA has blocked a limited number of rooms at the following hotel:

TRYP Barcelona Apolo Hotel
Avinguda del Paral·lel, 57-59,
08004, Barcelona, Spain
Tel: (34) 93 343 30 00
Fax: (34) 93 443 0059
E-mail: tryp.apolo@melia.com
 
at the rate of:
EUR 85.00 single use
incl. of breakfast, excl. of VAT and city tax

To make your reservation, please click here: http://meetings.melia.com/en/DIAEUROPE.html

Important: The room rate is available until 04 October 2014 or until the group block is sold-out, whichever comes first.
In case of no-shows the hotel is authorised to charge the full amount corresponding to the duration of your stay.

Contact Information 

Registration Questions
Phone.: +41 61 225 51 51
Fax: +41 61 225 51 52
Monday-Friday 8:00-17:00 CET
diaeurope@diaeurope.org

Agenda and Event Logistics
Magdalena Lewandowska, Event Manager
Phone: +41 61 225 51 65
Fax: +41 61 225 51 52
magdalena.lewandowska@diaeurope.org

Program Committee 

Previous Next

Agenda  

Day 1 Monday, Nov 10, 2014

  • 12:30PM - 2:00PM (Central Europe Standard Time)

    REGISTRATION AND WELCOME COFFEE
  • 2:00PM - 3:30PM (Central Europe Standard Time)

    LACK OF ADHERENCE AND THE CHOICE OF THE RIGHT ESTIMAND IN CLINICAL TRIALS


    Session Chair(s):

    • Norbert Benda, PhD
      Head of Biostatistics and Special Pharmacokinetics
      Federal Institute For Drugs and Medical Devices (BfArM), Germany
    • William Malbecq, DrSc
      Executive Director Biostatistics
      MSD Europe, Inc., Belgium

    LACK OF ADHERENCE AND THE CHOICE OF THE RIGHT ESTIMAND IN CLINICAL TRIALS

    Speaker(s):

    • Mouna Akacha
      Statistical Methodologist
      Novartis Pharma AG, Switzerland
    • The Estimand: An ugly necessity, a pie in the sky or a useful tool?
      Michael P O'Kelly, PhD, MA
      Senior Director, Centre for Statistics in Drug Development, Innovation
      Quintiles Ireland Ltd., Ireland
    • James Henry Roger, PhD, MA
      Director, Statistics and Programming
      United Kingdom
  • 3:30PM - 4:00PM (Central Europe Standard Time)

    COFFEE BREAK
  • 4:00PM - 5:30PM (Central Europe Standard Time)

    LACK OF ADHERENCE AND THE CHOICE OF THE RIGHT ESTIMAND IN CLINICAL TRIALS

    Speaker(s):

    • Applicability and appropriateness of de-facto and de-jure estimands in drug approval
      Ann-Kristin Leuchs
      Statistician
      Bfarm, Germany
    • David Brown
      Statistical Assessor
      MHRA, United Kingdom

Day 2 Tuesday, Nov 11, 2014

  • 9:00AM - 10:30AM (Central Europe Standard Time)

    STATISTICAL APPROACHES IN BIOSIMILARITY


    Session Chair(s):

    • Beatriz Seoane Núñez
      Expert Statistician
      Almirall, Spain
    • Ferran Torres, PhD
      Scientific Director, Biostatistics and Data
      Clinic Hospital of Barcelona, Spain

    A Biosimilar medicine is a growing field. The number of regulatory applications has increased in recent years. This session will highlight the features of the study design options for biosimilar efficacy trials. The choice of margins, their reliability and the different statistical and regulatory considerations associated with them will be some of the topics that will be discussed in this session from both a regulatory and industry point of view.

    Speaker(s):

    • Statistical Challenges in Biosimilarity - a regulator’s view
      Peter Volkers
      Biostatistician
      Paul Ehrlich Institute, Germany
    • Statistical challenges and current experience in biosimilarity trial designs
      Yulan Li
      Biostatistician
      Novartis, United States
  • 10:30AM - 11:00AM (Central Europe Standard Time)

    COFFEE BREAK
  • 11:00AM - 12:30PM (Central Europe Standard Time)

    HOW PRECISE CAN PRECISION MEDICINE BE?


    Session Chair(s):

    • Hans-Ulrich Burger
      Senior Director of Biostatistics
      F. Hoffmann-La Roche Ltd., Switzerland
    • Tim Friede, PhD
      Chair of Department of Medical Statistics
      Georg-August-University Goettingen, Germany

    Precision medicine becomes more and more important in drug development. Among the many topics possible we picked out two, biomarker identification and seamless enrichment designs. There will be a short introduction into the topic, an overview and different methods, then two examples from industry and a regulatory evaluation. Finally the two sessions will be rounded up by a panel discussion.

    Speaker(s):

    • Tim Friede, PhD
      Chair of Department of Medical Statistics
      Georg-August-University Goettingen, Germany
    • How Good is Your Biomarker? Comparison of Development Plans for Confirmatory Biomarker Enrichment
      Kaspar Rufibach
      Biostatistician, Oncology Biostatistics
      F. Hoffmann-La Roche AG, Switzerland
    • Heinz Schmidli, PhD, MSc
      Senior Expert Statistical Methodologist
      Novartis Pharma AG, Switzerland
  • 12:30PM - 2:00PM (Central Europe Standard Time)

    LUNCH
  • 2:00PM - 3:30PM (Central Europe Standard Time)

    Regulatory Views of Precision Medicine


    Session Chair(s):

    • Hans-Ulrich Burger
      Senior Director of Biostatistics
      F. Hoffmann-La Roche Ltd., Switzerland
    • Tim Friede, PhD
      Chair of Department of Medical Statistics
      Georg-August-University Goettingen, Germany
    • Norbert Benda, PhD
      Head of Biostatistics and Special Pharmacokinetics
      Federal Institute For Drugs and Medical Devices (BfArM), Germany

    Regulatory Views of Precision Medicine

    Speaker(s):

    • Key Issues in Enrichment Designs from a Development Point of View: An Introduction to the Panel Discussion
      Hans-Ulrich Burger
      Senior Director of Biostatistics
      F. Hoffmann-La Roche Ltd., Switzerland
  • 3:30PM - 4:00PM (Central Europe Standard Time)

    COFFEE BREAK
  • 4:00PM - 4:00PM (Central Europe Standard Time)

    KEY TOPICS IN REGULATORY STATISTICS


    Session Chair(s):

    • Hans-Ulrich Burger
      Senior Director of Biostatistics
      F. Hoffmann-La Roche Ltd., Switzerland
    • Tim Friede, PhD
      Chair of Department of Medical Statistics
      Georg-August-University Goettingen, Germany

    KEY TOPICS IN REGULATORY STATISTICS

    Speaker(s):

    • Peter Volkers
      Biostatistician
      Paul Ehrlich Institute, Germany
    • Andrew Peter Grieve, DrSc, PhD, MSc
      Senior Vice President Clinical Trial Methodology
      Aptiv Solutions, Germany

Registration Fees 

Other Fees

Student
€200.00

Member

Member Academia
€710.00
Member Government
€710.00
Member Standard
€1220.00
Member Standard (As of 09/29/2014)
€1420.00

Non-Member

NonMember Academia
€840.00
NonMember Government
€840.00
NonMember Standard
€1550.00
Register Online
« Back to Listing Back To Top